NCT07128771View on ClinicalTrials.gov

Cardiomodulatory Effects of Gender-Affirming Hormone Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

October 31, 2030

Conditions
Gender IncongruenceCardiovascular Disease (CVD) Risk Factors
Trial Locations (1)

Unknown

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

University of Oslo

OTHER

lead

University Hospital, Akershus

OTHER